| Description |
1 online resource |
| Series |
Handbook of Experimental Pharmacology ; volume 279 |
|
Handbook of experimental pharmacology ; v. 279.
|
| Contents |
2.3 The Auxiliary [beta]1a Subunit -- 2.4 The Adaptor Protein STAC3 -- 3 Skeletal Muscle Channelopathies -- 3.1 CaV1.1 Channelopathies -- 3.1.1 Hypokalemic Periodic Paralysis (HypoPP) -- 3.1.2 Normokalemic Periodic Paralysis (NormoPP) -- 3.1.3 CaV1.1 Related Myopathies -- 3.2 RyR1 Channelopathies -- 3.2.1 Central Core Disease (CCD) and Dusty Core Disease (DuCD) -- 3.2.2 Other Congenital Myopathies Caused by RyR1 Mutations -- 3.3 STAC3 Channelopathies -- 3.3.1 Native American Myopathy (NAM) -- 3.4 Channelopathies Caused by Several EC Coupling Proteins -- 3.4.1 Malignant Hyperthermia (MH) Susceptibility |
|
Intro -- Preface -- 1. A Bumpy Road Toward Drug Therapies in Ca2+ Channelopathies -- 2. Toward Advanced Technology Medicinal Products Targeting Ca2+-Channels -- 3. Ca2+-Channel Modulation: New Discoveries Answer (Very) Old Questions -- Contents -- Part I: Modulation -- CaV1.1 Calcium Channel Signaling Complexes in Excitation-Contraction Coupling: Insights from Channelopathies -- 1 Skeletal Muscle Excitation-Contraction (EC) Coupling -- 2 Essential Proteins for Skeletal Muscle Excitation-Contraction Coupling -- 2.1 The Voltage-Sensor CaV1.1 -- 2.2 The Calcium Release Channel RyR1 |
|
3.4.2 Myotonic Dystrophy Type 1 (DM1) -- 4 Summary and Perspective -- References -- Mechanisms of Vascular CaV1.2 Channel Regulation During Diabetic Hyperglycemia -- 1 Introduction -- 2 Role of CaV1.2 in Smooth Muscle Cells -- 3 Effects of Diabetic Hyperglycemia on Vascular CaV1.2 -- 4 Mechanisms -- 5 Pathophysiological Impact -- 6 Conclusions/Future Directions -- References -- Sympathetic Nervous System Regulation of Cardiac Calcium Channels -- 1 Introduction -- 2 Biophysical Signature of Adrenergic Regulation of L-Type Channels -- 3 Molecular Mechanisms Underlying L-Type Upregulation |
|
1 Cardiovascular CaV1.2 Channel at a Glance -- 2 Galectin-1 -- 2.1 Galectin-1 Overview -- 2.2 Galectin-1-Mediated CaV1.2 Regulation in Hypertension -- 2.3 Galectin-1 in Cardiac Diseases -- 2.4 Regulatory Signalling of Galectin-1 -- 2.5 Other Galectins -- 2.5.1 Galectin Localization and Functions -- 2.5.2 Galectin-3 in Cardiovascular Diseases -- 3 Cereblon -- 4 CaV1.2, Sialylation, and COVID-19 -- 5 Concluding Remarks -- References -- Part II: Pharmacological Approaches -- The Role of Striatal Cav1.3 Calcium Channels in Therapeutics for Parkinsonś Disease |
| Summary |
The aim of this volume is to summarize novel findings on the function, pathophysiology, and regulation of voltage-gated Ca2+ channels and on novel concepts of their pharmacological modulation. Impressive insights into the role of channel function and regulation have come from Ca2+ channelopathies affecting the pore-forming as well as accessory subunits and channel-interacting proteins. Moreover, the long-sought molecular basis for key regulatory pathways have been discovered as well as exciting concepts of their subtype-selective pharmacological modulation |
| Notes |
Online resource; title from PDF title page (SpringerLink, viewed August 11, 2023) |
| Subject |
Calcium channels.
|
| Form |
Electronic book
|
| Author |
Striessnig, Jörg.
|
| ISBN |
9783031384370 |
|
3031384377 |
|
